HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $22 Price Target
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $22 price target.
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $22 price target.